Sunday, July 15, 2007


Jul. 15, 2007 (McClatchy-Tribune Regional News delivered by Newstex) --
WR Hambrecht has published an updated review for Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) (Nasdaq: TEVA; TASE: TEVA), in which it reiterated its 'Buy' rating and set a target price of $50. This is a 15 percent premium over Teva's closing price on Friday.

Echoing previous positive forecasts from Goldman Sachs (OOTC:GSGRP) (NYSE:GS) and Bear Sterns for Teva's second quarter results, WR Hambrecht says, 'Our $0.55 earnings per share estimate is essentially in line with the consensus estimate of $0.56. Multiple upside potential comes from the recently launched Lotrel, which is a $1.4 billion product enjoying exclusivity until the end of this year. Further, with competition withdrawing from the generic OxyContin market, which is a $2 billion product, Teva was able to significantly expand its market share with favorable pricing.'

As for Teva's ethical blockbuster drug, Copaxone for multiple sclerosis, WR Hambrecht says, 'we forecast sales for the quarter of $410 million, up 15 percent year-over-year.'

Newstex ID: KRTB-0262-18145701


Delivered by Newstex LLC
via theFinancials.com